| A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus (NCT07405970) | Beijing Mabworks Biotech Co., Ltd. | 2026-04-10 |
| A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. (NCT07375758) | Beijing Mabworks Biotech Co., Ltd. | 2026-02-05 |
| A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. (NCT06232096) | Beijing Mabworks Biotech Co., Ltd. | 2024-02-22 |
| A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL (NCT05806099) | Beijing Mabworks Biotech Co., Ltd. | 2023-06-28 |
| A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy (NCT05862233) | Beijing Mabworks Biotech Co., Ltd. | 2023-06-02 |
| A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus (NCT05796206) | Beijing Mabworks Biotech Co., Ltd. | 2023-05-26 |
| A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) (NCT05314010) | Beijing Mabworks Biotech Co., Ltd. | 2022-08-18 |
| A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy (NCT05398653) | Beijing Mabworks Biotech Co., Ltd. | 2022-02-24 |
| Treatment of Advanced and Metastatic Solid Tumors With MIL97 (NCT04965077) | Beijing Mabworks Biotech Co., Ltd. | 2022-01-18 |
| Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis (NCT07044115) | Beijing Mabworks Biotech Co., Ltd. | 2021-11-26 |
| MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma (NCT04834024) | Beijing Mabworks Biotech Co., Ltd. | 2021-06-02 |
| A Clinical Study of MIL93 in Solid Tumors. (NCT04671875) | Beijing Mabworks Biotech Co., Ltd. | 2021-04-21 |
| A Clinical Study of MIL95 in Advanced Malignancies. (NCT04651348) | Beijing Mabworks Biotech Co., Ltd. | 2021-01-04 |
| MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) (NCT04110301) | Beijing Mabworks Biotech Co., Ltd. | 2019-11-28 |
| Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor (NCT03842085) | Beijing Mabworks Biotech Co., Ltd. | 2019-04-11 |